Publications by authors named "Christina Ottis"
Article Synopsis
- COVID-19 vaccination significantly reduces the risk of severe outcomes from COVID-19 in children, including MIS-C and death, leading to recommendations for various age groups from 6 months to 16 years and older between late 2020 and mid-2022.
- The U.S. government worked with multiple partners to ensure widespread vaccine distribution, but vaccination rates among children have lagged behind those of adults, with only 61.8% of children aged 12-17, 32.9% aged 5-11, and 5.5% aged 6 months-4 years vaccinated as of May 2023.
- The manuscript details the planning and execution of the COVID-19 pediatric vaccination program, highlighting
On October 29, 2021, the Pfizer-BioNTech pediatric COVID-19 vaccine received Emergency Use Authorization for children aged 5-11 years in the United States. For a successful immunization program, both access to and uptake of the vaccine are needed. Fifteen million doses were initially made available to pediatric providers to ensure the broadest possible access for the estimated 28 million eligible children aged 5-11 years, especially those in high social vulnerability index (SVI) communities.
View Article and Find Full Text PDFWe analyzed first-dose coronavirus disease vaccination coverage among US children 5-11 years of age during November-December 2021. Pediatric vaccination coverage varied widely by jurisdiction, age group, and race/ethnicity, and lagged behind vaccination coverage for adolescents aged 12-15 years during the first 2 months of vaccine rollout.
View Article and Find Full Text PDF